CJC-1295 WITH DAC - Research Grade Peptide

CJC-1295 WITH DAC – Research Grade Peptide

For research purposes only. This product is supplied exclusively for scientific laboratory research and analytical purposes. It is not intended for human or animal use, consumption, clinical use or therapeutic application. It must not be used in any way that contravenes applicable laws or the requirements of the Medicines and Healthcare products Regulatory Agency.

• Research-grade synthetic CJC-1295 peptide with batch documentation available where supplied
• Defined 30-residue modified peptide containing the C-terminal DAC-associated maleimide group
• Chromatographic purity of at least 99% where confirmed by the applicable batch Certificate of Analysis
• Supplied as lyophilised laboratory material in sealed flip-top headspace vials
• Batch identity, chromatographic purity, peptide content and analytical specifications stated in the applicable Certificate of Analysis
• Handled and supplied exclusively as a research-use laboratory material

All of our research peptides and related laboratory materials are supplied strictly for scientific research and laboratory use only. Each vial contains lyophilised material prepared to support consistent laboratory handling and storage. The stated nominal amount refers to the declared CJC-1295 WITH DAC peptide content of a single vial, subject to the applicable batch documentation. Where dissolution or reconstitution is required, the solvent, buffer, concentration, handling procedure and storage conditions stated in the applicable Certificate of Analysis, Safety Data Sheet or validated laboratory method should be followed. We do not provide advice or recommendations concerning dosage, administration or use in humans or animals.

Chemical Information:

• Product Name: CJC-1295 WITH DAC
• Alternative Names: CJC-1295; CJC1295; maleimido-modified GRF 1–29 analogue
• Chemical Classification: Synthetic modified 30-residue peptide
• Reference Structural Description: Tetrasubstituted human growth hormone-releasing factor 1–29 analogue containing an additional C-terminal lysine bearing an N^ε-3-maleimidopropionamide group
• Sequence Length: 30 amino-acid residues, including the additional modified C-terminal lysine
• Peptide Sequence: H-Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-Lys-NH₂
• Sequence Modifications: D-alanine at position 2, glutamine at position 8, alanine at position 15 and leucine at position 27
• DAC-Associated Modification: The epsilon amino group of the additional C-terminal lysine carries a 3-maleimidopropionamide group
• N-Terminal Structure: Free amino terminus
• C-Terminal Structure: Modified C-terminal lysinamide
• Primary CAS Number: 446262-90-4
• Historical or Deprecated CAS Reference: 863288-34-0
• PubChem Compound Identifier: CID 91971820
• UNII: 62RC32V9N7
• Molecular Formula: C₁₆₅H₂₆₉N₄₇O₄₆
• Average Molecular Weight: Approximately 3647.2 g/mol
• Purity Specification: At least 99% chromatographic purity where confirmed by the applicable batch Certificate of Analysis and stated analytical method
• Physical Form: Lyophilised laboratory material, as stated in the applicable batch Certificate of Analysis
• Appearance: Refer to the applicable batch Certificate of Analysis
• Supplied Molecular Form: Maleimide-functionalised CJC-1295 peptide prior to albumin conjugation; the supplied vial does not contain an albumin-peptide complex unless expressly stated in the applicable batch documentation
• Product Distinction: CJC-1295 WITH DAC contains the additional modified C-terminal lysine. CJC-1295 MOD GRF 1-29 / WITHOUT DAC does not contain this structural modification and has a different molecular formula and molecular weight
• Counter-Ion or Salt Form: Refer to the applicable Certificate of Analysis, as acetate, trifluoroacetate or another counter-ion may affect the measured mass and net peptide content of the supplied material
• Identity Confirmation: Product identity should be supported by sequence records and mass-spectrometry results consistent with the specified modified peptide
• Analytical Interpretation: Chromatographic purity, net peptide content, molecular identity, water content, residual solvent content and counter-ion content are separate analytical measurements and should be interpreted together

✓ Batch documentation – Certificate of Analysis documentation is provided where supplied for review.
✓ Certificate of Analysis – Accessible through the product QR code where provided for the applicable batch.
✓ Safety Data Sheet – Supplied to support appropriate laboratory handling, storage and regulatory compliance.
✓ Sequence documentation – Peptide sequence, amino-acid substitutions and the C-terminal DAC-associated modification should be confirmed using the applicable batch records.
✓ Mass-spectrometry documentation – Molecular identity should be supported by analytical mass data consistent with the specified modified CJC-1295 construct.
✓ Purity documentation – The reported chromatographic purity applies only to the analytical method and batch stated in the Certificate of Analysis.
✓ Peptide-content documentation – Net peptide content should be distinguished from chromatographic purity and interpreted alongside water and counter-ion results.
✓ Counter-ion documentation – Acetate, trifluoroacetate or another counter-ion should be identified and quantified where applicable.
✓ Supplier documentation – Reviewed where supporting synthesis, purification and analytical records are supplied.
✓ Fast, reliable and trackable delivery – Securely packaged and dispatched using insulated or temperature-controlled packaging where required by the applicable transport and storage specification.

For Research Use Only
This product is supplied strictly for scientific research, laboratory analysis and experimental work. It is not intended for human consumption, animal use, clinical use, diagnostic use or any form of therapeutic application.

CJC-1295 WITH DAC Product Overview

Our CJC-1295 WITH DAC research-grade synthetic peptide is supplied for controlled scientific laboratory investigation, analytical method development, peptide characterisation, high-performance liquid chromatography assessment and mass-spectrometry workflows. The material comprises a defined modified 30-residue peptide structure containing four specified amino-acid substitutions and an additional C-terminal lysine carrying a maleimidopropionamide group.

The material is handled with a focus on batch traceability, documented quality control and consistent laboratory presentation. Product identity, chromatographic purity, net peptide content, molecular form, amino-acid sequence, modified-residue integrity, counter-ion content, water content, residual solvents, bacterial endotoxin results and other analytical specifications should be confirmed using the applicable batch Certificate of Analysis. Chromatographic purity should not automatically be interpreted as equivalent to the total net peptide content of the vial.

For the majority of routine analytical, investigative and general laboratory work, the Regular CJC-1295 WITH DAC specification remains highly suitable. The premium black-and-gold ULTIMATE CJC-1295 WITH DAC option provides an additional preparative high-performance liquid chromatography purification stage and a more stringent bacterial endotoxin and lipopolysaccharide testing specification for scientific projects requiring enhanced quality-control parameters.

View Certificate of Analysis

View Safety Data Sheet